Medication 9: Selpercatinib (Retevmo) – Homing in on RET-Driven Cancers
Selpercatinib, commercially known as Retevmo, provides a new ray of hope for patients with RET-driven cancers. This medication is tailored to specifically inhibit the rearranged during transfection (RET) protein, which can drive the growth of certain thyroid cancers.
Selpercatinib hones in on this RET protein, effectively blocking its action. The medication thereby disrupts the cancer cells’ growth and proliferation, offering an effective line of treatment for cancers driven by this particular protein.
The effectiveness of Selpercatinib in RET-driven cancers underscores the promise of personalized medicine. In those instances where thyroid cancer is driven by the RET protein, Selpercatinib can make a tangible difference, bolstering treatment outcomes.
Despite its targeted action, Selpercatinib does have its side effects. These can range from dry mouth and diarrhea to hypertension and liver function abnormalities. It’s crucial for patients to discuss any side effects they experience with their healthcare provider to ensure optimal management.
In summary, Selpercatinib offers a potent, personalized treatment option for patients with RET-driven cancers. Its unique mechanism of action makes it a vital weapon in the arsenal against thyroid cancer. (9)
